Heartburn and indigestion on Foundayo™

Two label rows that cover heartburn

Both entries come from Table 1 in section 6.1, which pools Trials 1 and 2, the ATTAIN-1 and ATTAIN-2 studies: adults with obesity or overweight, with or without type 2 diabetes, treated for up to 72 weeks ^[1]. The table only lists reactions seen in at least 5% of treated adults and more often than with placebo, so both made the cut on every dose. The US label approves Foundayo™ for weight management only ^[1].

The Medication Guide uses plainer words for the same reactions, heartburn and indigestion, and puts both among the most common side effects ^[2]. The European medicines committee’s positive opinion of 15 October 2026 gives nausea, vomiting and diarrhea as examples of common side effects, and there is no EMA product information yet; Health Canada has no Foundayo™ entry ^[3][4].

Indigestion was the bigger of the two

Dyspepsia was reported about twice as often as reflux disease at every dose. Like constipation, it peaked on the middle dose: 16% on 9 mg against 13% on 17.2 mg ^[1]. Reflux disease barely moved with the dose, sitting between 6% and 7%, roughly three times the placebo figure.

Someone with both might be counted in both rows, so the two percentages cannot simply be added to give a total for heartburn. The label does not report a combined figure, and it gives no timing for either reaction, unlike nausea, vomiting and diarrhea, which it says became less frequent after escalation ^[1].

Registry rows, including a comparison with oral semaglutide

ATTAIN-1 and ATTAIN-2 posted every non-serious event that reached 5% in any group, and ACHIEVE-3, a 52-week trial comparing orforglipron with oral semaglutide in type 2 diabetes treated with metformin, used the same threshold ^[5][6][7]. ACHIEVE-3 was open label: participants knew which tablet they took, which can influence what gets reported.

What the head-to-head trial adds

In the ATTAIN trials, the 6, 12 and 36 mg trial doses correspond to Foundayo™ 5.5, 9 and 17.2 mg, and both reproduce the label’s middle-dose peak for indigestion ^[1][5][6]. ACHIEVE-3 used its own trial doses in diabetes, which the US label does not cover.

In the published ACHIEVE-3 results, stomach and bowel events of any kind affected 59% on orforglipron 12 mg and 58% on 36 mg, against 37% on oral semaglutide 7 mg and 45% on 14 mg, and more people stopped orforglipron because of adverse events (9% and 10% against 4% and 5%) ^[8]. Dyspepsia and reflux disease pointed the same way in the registry ^[7]. Because the trial was open label, the size of the gap is best read with caution.

Why the tablet can bring on burning and fullness

Supported by the label: section 12.2 states that Foundayo™ delays gastric emptying, with the largest delay after the first dose and a smaller one over time ^[1]. The label lists this among the tablet’s effects but does not itself tie dyspepsia or reflux to it ^[1].

Supported by a public health source: NIDDK lists GLP-1 receptor agonists among the medicines that may cause indigestion ^[11]. Not measured: NIDDK describes the lower esophageal sphincter, the valve at the bottom of the food pipe, together with the diaphragm as the main barrier against reflux ^[9]; whether orforglipron affects that valve is not reported in the sources reviewed here.

Background: NIDDK names overweight and obesity among factors that can lead to reflux disease ^[9], so heartburn was not rare in the trial population to begin with, as the placebo rows show.

Other things that cause heartburn and indigestion

• Pregnancy, smoking or second-hand smoke, and a hiatal hernia ^[9].
• Medicines including NSAID painkillers, calcium channel blockers for blood pressure, some asthma medicines, benzodiazepines and tricyclic antidepressants ^[9].
• For indigestion in particular: some antibiotics, iron supplements, osteoporosis medicines and corticosteroids ^[11].
• Peptic ulcers and infections such as Helicobacter pylori ^[11].
• Functional dyspepsia, a disorder of how the gut and brain work together, which NIDDK says accounts for most long-lasting indigestion ^[11].
• Large or fatty meals, bending over, alcohol and lying down soon after eating ^[12].

What public health sources suggest

NIDDK’s lifestyle list for reflux includes losing weight if you are overweight, raising the head of the bed, stopping smoking and changing eating habits ^[10]. Cleveland Clinic adds smaller meals, leaving time between eating and lying down, avoiding tight clothing and cutting back on the foods that set off your symptoms; it names chocolate, coffee, alcohol, mint, garlic and onions as frequent culprits ^[12]. During an episode it suggests standing up, taking small sips of water and loosening a waistband ^[12].

Both sources describe antacids, H2 blockers and proton pump inhibitors, and NIDDK cautions against using antacids every day or for severe symptoms without talking to a doctor ^[10][12]. For Foundayo™ the relevant label fact is narrow: in the interaction study, esomeprazole 40 mg once daily, a proton pump inhibitor, had no effect on orforglipron’s total exposure or peak level (section 12.3, Table 4) ^[1]. The label has no data on antacids or H2 blockers. This is a finding about absorption, not advice to take anything; whether an acid medicine suits you is for a pharmacist or your prescriber.

Tablet points that touch the stomach

The label says Foundayo™ is taken once a day with or without food and swallowed whole, not broken, crushed or chewed (section 2.1) ^[1]. Its food study, run with a higher investigational tablet, found no clinically relevant effect of food on exposure (section 12.3) ^[1], and the label does not link meal timing to reflux. Moving the tablet to another time of day is a question for your prescriber.

Two warnings sit close to this topic. The Medication Guide asks you to mention severe stomach problems such as slowed emptying before starting, and the label does not recommend the tablet in severe gastroparesis (section 5.3) ^[1][2]. And before any procedure under anaesthesia or deep sedation, such as an upper endoscopy for reflux ^[12], tell the team you take Foundayo™, because a slower stomach can raise the risk of aspiration (section 5.9) ^[1].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.